Novo Nordisk
NVO
1,350 hedge funds and large institutions have $15.6B invested in Novo Nordisk in 2026 Q2 according to their latest regulatory filings, with 215 funds opening new positions, 464 increasing their positions, 459 reducing their positions, and 117 closing their positions.
84% more first-time investments, than exits
New positions opened: 215 | Existing positions closed: 117
27% more funds holding in top 10
Funds holding in top 10: 11 → 14 (+3)
26% more capital invested
Capital invested by funds: $12.4B → $15.6B (+$3.26B)
6% more funds holding
Funds holding: 1,277 → 1,350 (+73)
1% more repeat investments, than reductions
Existing positions increased: 464 | Existing positions reduced: 459
0.01% more ownership
Funds ownership: 9.62% → 9.62% (+0.01%)
9% less call options, than puts
Call options by funds: $2.35B | Put options by funds: $2.58B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FAM
Fred Alger Management
New York
|
+$211M |
| 2 |
Goldman Sachs
New York
|
+$174M |
| 3 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$129M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$128M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$98.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$270M |
| 2 |
Two Sigma Investments
New York
|
-$269M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$131M |
| 4 |
Capital International Investors
Los Angeles,
California
|
-$89.1M |
| 5 |
Jane Street
New York
|
-$87M |
NVO Hedge Fund Activity: Q2 2026 in Review
1,350 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q2 2026, worth a combined $15.6B — up 26% from $12.4B a quarter earlier.
Buyers outnumbered sellers: 215 funds opened new NVO positions and 117 closed out — a net gain of 98 holders — while 464 added to existing stakes and 459 trimmed.
The largest buyer was Fred Alger Management, opening a new position worth an estimated $211M. The largest seller was Susquehanna International Group, cutting an estimated $270M.
- 1,350 institutional investors held Novo Nordisk (NVO) as of Q2 2026, up from 1,277 in Q1 2026.
- Funds reported $15.6B of Novo Nordisk stock for Q2 2026, up 26% quarter-over-quarter.
- 215 funds opened new Novo Nordisk positions in Q2 2026 and 117 closed out, a net change of +98 holders.
- The largest Novo Nordisk buyer in Q2 2026 was Fred Alger Management, an estimated $211M added.
- The largest Novo Nordisk seller in Q2 2026 was Susquehanna International Group, an estimated $270M sold.
Based on aggregated 13F filings for Q2 2026.